<DOC>
	<DOCNO>NCT00525902</DOCNO>
	<brief_summary>The purpose study assess safety efficacy Adalimumab uveitis .</brief_summary>
	<brief_title>Adalimumab ( Humira ) Treatment Refractory Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Patients visionthreatening autoimmune uveitis . 2 . Failure respond prednisone least one systemic immunosuppressive ( methotrexate , azathioprine , mycophenolate mofetil , cyclosporine , cyclophosphamide , chlorambucil ) , intolerance medication due side effect . 1 . Serious concomitant illness could interfere subject 's participation trial . 2 . Previous current use cyclophosphamide . 3 . Unable unwilling undergo multiple injection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>